NEW YORK (GenomeWeb) – Vermillion said today that CareFirst Blue Cross/Blue Shield has begun covering the company's OVA1 ovarian cancer test.

According to Vermillion, CareFirst is the largest insurer in Maryland, covering 3.4 million people, representing more than 40 percent of the state's population.

With the announcement, Vermillion now has commercial coverage for OVA1 for more than 16 million lives. The company received another positive coverage decision for the test in April from Blue Cross/Blue Shield of Michigan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.